ASND Form 144: 10,000 ADS from Warrant Exercise to Trade on NASDAQ

Rhea-AI Filing Summary

Form 144 reports a proposed sale of 10,000 American Depositary Shares (ADS) of Ascendis Pharma (ASND) with an aggregate market value of $1,925,734.17. The sale is to be handled through Merrill Lynch on NASDAQ and is scheduled for 08/12/2025. Based on the figures provided, the implied price per ADS is approximately $192.57.

The shares were acquired the same day by warrant exercise from Ascendis Pharma A/S and paid for in cash. The 10,000 ADS represent about 0.0165% of the 60,454,589 ADS outstanding reported in the filing. The filer notes no securities sold in the past three months for the account in question.

Positive

• Small relative size: 10,000 ADS equal ~0.0165% of 60,454,589 outstanding ADS, implying negligible market impact
• Clear acquisition and payment: Shares were acquired by warrant exercise and paid in cash, with broker details provided (Merrill Lynch)

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine, small-scale sale of newly exercised ADS via broker; negligible market impact.

The filing documents a proposed sale of 10,000 ADS acquired by warrant exercise on the same date and paid in cash, executed through Merrill Lynch on NASDAQ. At an aggregate value of $1.925M, the position equals roughly 0.0165% of outstanding ADS, which is immaterial to market liquidity or capitalization. The lack of reported sales in the prior three months suggests this is an isolated disposition tied to immediate monetization of exercised warrants rather than a sustained selling trend.

Corporate Governance Expert

TL;DR: Documentation is compliant and transparent; transaction appears procedural rather than strategically significant.

The Form 144 supplies the required elements: class of securities, broker, quantity, aggregate value, acquisition method, and payment nature. The shares were acquired via warrant exercise from Ascendis Pharma A/S and scheduled for sale the same day, with cash payment noted. From a governance standpoint, the filing meets disclosure standards and the transaction size relative to total ADS outstanding is minimal, limiting any corporate-governance implications.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	10000	1925734.17	60454589	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	08/12/2025	Warrant exercise	Ascendis Pharma A/S			10000	08/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ASND Form 144 report?

The Form 144 reports a proposed sale of 10,000 Ascendis Pharma (ASND) American Depositary Shares (ADS) valued at $1,925,734.17, to be sold on NASDAQ via Merrill Lynch.

How were the 10,000 ADS acquired?

The ADS were acquired on 08/12/2025 by warrant exercise from Ascendis Pharma A/S and payment was made in cash.

What percentage of outstanding shares does the proposed sale represent for ASND?

The 10,000 ADS represent approximately 0.0165% of the 60,454,589 ADS outstanding reported in the filing.

What is the implied price per ADS in this filing?

Based on the aggregate market value of $1,925,734.17 for 10,000 ADS, the implied price is about $192.57 per ADS.

Were there any other sales in the past three months reported for this account?

The filing states: "Nothing to Report" for securities sold during the past 3 months by the person for whose account the securities are to be sold.